{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5","value":"79.7"},{"groupId":"OG001","spread":"23.7","value":"78.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2313"},{"groupId":"OG001","value":"2317"}],"units":"Participants"}],"title":"Baseline: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.7","value":"-12.9"},{"groupId":"OG001","spread":"25.2","value":"-13.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2048"},{"groupId":"OG001","value":"2086"}],"units":"Participants"}],"title":"Change at Week 13: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"-7.6"},{"groupId":"OG001","spread":"23.4","value":"-7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2020"},{"groupId":"OG001","value":"2050"}],"units":"Participants"}],"title":"Change at Week 25: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"-4.9"},{"groupId":"OG001","spread":"24.6","value":"-6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2261"}],"units":"Participants"}],"title":"Change at EOT: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.3","value":"-0.1"},{"groupId":"OG001","spread":"23.3","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1887"},{"groupId":"OG001","value":"1889"}],"units":"Participants"}],"title":"Change at FU Month 18: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.6","value":"0.5"},{"groupId":"OG001","spread":"23.5","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1839"},{"groupId":"OG001","value":"1852"}],"units":"Participants"}],"title":"Change at FU Month 24: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.4","value":"1.7"},{"groupId":"OG001","spread":"24.6","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1789"},{"groupId":"OG001","value":"1758"}],"units":"Participants"}],"title":"Change at FU Month 36: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.8","value":"54.0"},{"groupId":"OG001","spread":"30.7","value":"55.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"966"},{"groupId":"OG001","value":"997"}],"units":"Participants"}],"title":"Baseline: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"-16.5"},{"groupId":"OG001","spread":"27.2","value":"-13.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"530"},{"groupId":"OG001","value":"553"}],"units":"Participants"}],"title":"Change at Week 13: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.8","value":"-11.9"},{"groupId":"OG001","spread":"26.5","value":"-7.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"558"},{"groupId":"OG001","value":"630"}],"units":"Participants"}],"title":"Change at Week 25: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.5","value":"-10.7"},{"groupId":"OG001","spread":"27.7","value":"-8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"781"},{"groupId":"OG001","value":"820"}],"units":"Participants"}],"title":"Change at EOT: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.5","value":"-4.2"},{"groupId":"OG001","spread":"26.5","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"585"},{"groupId":"OG001","value":"581"}],"units":"Participants"}],"title":"Change at FU Month 18: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"-6.0"},{"groupId":"OG001","spread":"27.6","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"576"},{"groupId":"OG001","value":"561"}],"units":"Participants"}],"title":"Change at FU Month 24: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.1","value":"-5.3"},{"groupId":"OG001","spread":"26.8","value":"-6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"530"},{"groupId":"OG001","value":"541"}],"units":"Participants"}],"title":"Change at FU Month 36: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"19.6"},{"groupId":"OG001","spread":"24.3","value":"20.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2260"}],"units":"Participants"}],"title":"Baseline: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"-5.6"},{"groupId":"OG001","spread":"20.7","value":"-6.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1969"},{"groupId":"OG001","value":"2008"}],"units":"Participants"}],"title":"Change at Week 13: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"-2.6"},{"groupId":"OG001","spread":"20.9","value":"-2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1945"},{"groupId":"OG001","value":"1975"}],"units":"Participants"}],"title":"Change at Week 25: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"-1.0"},{"groupId":"OG001","spread":"21.2","value":"-1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2176"},{"groupId":"OG001","value":"2191"}],"units":"Participants"}],"title":"Change at EOT: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"2.5"},{"groupId":"OG001","spread":"21.7","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1814"},{"groupId":"OG001","value":"1820"}],"units":"Participants"}],"title":"Change at FU Month 18: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"2.8"},{"groupId":"OG001","spread":"22.7","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1757"},{"groupId":"OG001","value":"1778"}],"units":"Participants"}],"title":"Change at FU Month 24: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.0","value":"2.6"},{"groupId":"OG001","spread":"23.6","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1711"},{"groupId":"OG001","value":"1685"}],"units":"Participants"}],"title":"Change at FU Month 36: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.7","value":"51.3"},{"groupId":"OG001","spread":"31.5","value":"50.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2312"},{"groupId":"OG001","value":"2318"}],"units":"Participants"}],"title":"Baseline: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.2","value":"3.1"},{"groupId":"OG001","spread":"31.9","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2043"},{"groupId":"OG001","value":"2090"}],"units":"Participants"}],"title":"Change at Week 13: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.1","value":"6.3"},{"groupId":"OG001","spread":"31.2","value":"5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2020"},{"groupId":"OG001","value":"2052"}],"units":"Participants"}],"title":"Change at Week 25: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.2","value":"7.7"},{"groupId":"OG001","spread":"31.8","value":"6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2238"},{"groupId":"OG001","value":"2263"}],"units":"Participants"}],"title":"Change at EOT: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.0","value":"12.9"},{"groupId":"OG001","spread":"32.0","value":"10.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1887"},{"groupId":"OG001","value":"1884"}],"units":"Participants"}],"title":"Change at FU Month 18: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.9","value":"13.7"},{"groupId":"OG001","spread":"32.9","value":"12.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1836"},{"groupId":"OG001","value":"1849"}],"units":"Participants"}],"title":"Change at FU Month 24 : FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.1","value":"14.7"},{"groupId":"OG001","spread":"32.9","value":"13.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1785"},{"groupId":"OG001","value":"1752"}],"units":"Participants"}],"title":"Change at FU Month 36: FP"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2313"},{"groupId":"OG001","value":"2318"}],"units":"Participants"}],"description":"EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \\[FP\\]) and four symptom scales (systemic side effects \\[SE\\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"MEAN","populationDescription":"ITT population. Overall number of participants analyzed=participants evaluable for this outcome measure. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}